Cirrhosis primary prevention

Jump to navigation Jump to search

Cirrhosis Microchapters


Patient Information


Historical Perspective




Differentiating Cirrhosis from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings


Chest X Ray



Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Cirrhosis primary prevention On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Cirrhosis primary prevention

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cirrhosis primary prevention

CDC on Cirrhosis primary prevention

Cirrhosis primary prevention in the news

Blogs on Cirrhosis primary prevention

Directions to Hospitals Treating Cirrhosis

Risk calculators and risk factors for Cirrhosis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2] Sudarshana Datta, MD [3]


Primary prevention of cirrhosis includes avoidance of causative agents such as alcohol, high doses of certain supplements (vitamin A, copper and iron) and vaccination against hepatitis. Adequate caloric intake, physical activity, prevention of high risk behaviors, screening of blood products and vaccination for Hepatitis B play an important role in primary prevention.

Primary Prevention


  1. Wiegand J, Berg T (2013). "The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis". Dtsch Arztebl Int. 110 (6): 85–91. doi:10.3238/arztebl.2013.0085. PMC 3583179. PMID 23451000.
  2. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Crocè L, Sasso F, Pozzato G, Cristianini G, Brandi G (1997). "Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group". Gut. 41 (6): 845–50. PMC 1891602. PMID 9462221.
  3. Friedmann PD (2013). "Clinical practice. Alcohol use in adults". N. Engl. J. Med. 368 (4): 365–73. doi:10.1056/NEJMcp1204714. PMID 23343065.
  4. Mazoit JX, Sandouk P, Zetlaoui P, Scherrmann JM (1987). "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects". Anesth. Analg. 66 (4): 293–8. PMID 3565791.
  5. Tegeder I, Geisslinger G, Lötsch J (1999). "[Therapy with opioids in liver or renal failure]". Schmerz (in German). 13 (3): 183–95. doi:10.1007/s004829900019. PMID 12799931.
  6. Zimmerman HJ, Maddrey WC (1995). "Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure". Hepatology. 22 (3): 767–73. PMID 7657281.
  7. Kuffner EK, Dart RC, Bogdan GM, Hill RE, Casper E, Darton L (2001). "Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial". Arch. Intern. Med. 161 (18): 2247–52. PMID 11575982.
  8. Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ (2011). "Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease". J. Hepatol. 54 (4): 753–9. doi:10.1016/j.jhep.2010.07.040. PMC 3060962. PMID 21126792.
  9. Lieber CS, Rubin E (1968). "Alcoholic fatty liver in man on a high protein and low fat diet". Am. J. Med. 44 (2): 200–6. PMID 5635674.
  10. Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, Hoofnagle JH (2010). "Increased caffeine consumption is associated with reduced hepatic fibrosis". Hepatology. 51 (1): 201–9. doi:10.1002/hep.23279. PMC 2801884. PMID 20034049.
  11. Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA (1984). "Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis". Am. J. Med. 76 (2): 211–22. PMID 6421159.
  12. Eckman MH, Kaiser TE, Sherman KE (2011). "The cost-effectiveness of screening for chronic hepatitis B infection in the United States". Clin. Infect. Dis. 52 (11): 1294–306. doi:10.1093/cid/cir199. PMC 3097367. PMID 21540206.
  13. Wörns MA, Teufel A, Kanzler S, Shrestha A, Victor A, Otto G, Lohse AW, Galle PR, Höhler T (2008). "Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases". Am. J. Gastroenterol. 103 (1): 138–46. doi:10.1111/j.1572-0241.2007.01609.x. PMID 17970833.
  14. Chu CM, Liaw YF (2005). "Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology". Infection. 33 (3): 136–9. doi:10.1007/s15010-005-4094-4. PMID 15940414.
  15. Wedemeyer H, Hofmann WP, Lueth S, Malinski P, Thimme R, Tacke F, Wiegand J (2010). "[ALT screening for chronic liver diseases: scrutinizing the evidence]". Z Gastroenterol (in German). 48 (1): 46–55. doi:10.1055/s-0028-1109980. PMID 20072996.
  16. Breitling LP, Claessen H, Drath C, Arndt V, Brenner H (2011). "Gamma-glutamyltransferase, general and cause-specific mortality in 19,000 construction workers followed over 20 years". J. Hepatol. 55 (3): 594–601. doi:10.1016/j.jhep.2010.12.029. PMID 21256904.
  17. Claessen H, Brenner H, Drath C, Arndt V (2010). "Gamma-glutamyltransferase and disability pension: a cohort study of construction workers in Germany". Hepatology. 51 (2): 482–90. doi:10.1002/hep.23324. PMID 19967717.
  18. Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H (2009). "Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels". Hepatology. 50 (5): 1403–11. doi:10.1002/hep.23135. PMID 19670414.
  19. Bell BP, Manos MM, Zaman A, Terrault N, Thomas A, Navarro VJ, Dhotre KB, Murphy RC, Van Ness GR, Stabach N, Robert ME, Bower WA, Bialek SR, Sofair AN (2008). "The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance". Am. J. Gastroenterol. 103 (11): 2727–36, quiz 2737. doi:10.1111/j.1572-0241.2008.02071.x. PMID 18684170.

Template:WH Template:WS